Levosimendan Infusion in Critically Ill Patients With Cardiogenic Shock
Conditions:   Cardiogenic Shock;   Cardiorenal Syndrome;   Acute Kidney Failure Intervention:   Drug: Levosimendan Sponsor:   University of Zurich Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 8, 2021 Category: Research Source Type: clinical trials

Evaluation of Oxiris Membrane as a Treatment for Ischemia-reperfusion Syndrome in Cardiogenic Shock Treated With Extracorporeal Life Support (ECMO/ECLS): A Randomized Pilot Study ECMORIX
Condition:   Cardiogenic Shock Interventions:   Device: Oxiris membrane;   Device: Prismaflex membrane;   Biological: Blood tests Sponsor:   Centre Hospitalier Universitaire Dijon Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 13, 2021 Category: Research Source Type: clinical trials

Scoring Model for Predicting Outcome in Patients With Cardiogenic Shock
Condition:   Cardiogenic Shock Intervention:   Other: no intervention, this is an observational study Sponsor:   National Taiwan University Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 20, 2021 Category: Research Source Type: clinical trials

Impact of intravenous lidocaine on clinical outcomes of patients with ARDS during COVID-19 pandemia (LidoCovid): A structured summary of a study protocol for a randomised controlled trial
This study has been conducted at the University Hospitals of Strasbourg (medical and surgical Intensive Care Units in Hautepierre Hospital) since the 4th November 2020. The participants are 18 years-old and older, hospitalized in ICU for a moderate to severe ARDS according to the Berlin definition; they have to be intubated and sedated for mechanical protective ventilation. All participants are affiliated to the French Social security system and a dosage of beta HCG has to be negative for women of child bearing age .For the Covid-19 subgroup, the SARS-CoV2 infection is proved by RT-PCR
Source: Trials - February 11, 2021 Category: Research Source Type: clinical trials

LEVOSIMENDAN to Facilitate Weaning From ECMO in Severe Cardiogenic Shock Patients
Conditions:   Cardiogenic Shock;   Extracorporeal Membrane Oxygenation Complication Interventions:   Drug: Levosimendan;   Drug: Placebo of Levosimendan Sponsor:   Assistance Publique - Hôpitaux de Paris Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 28, 2021 Category: Research Source Type: clinical trials

Cardiogenic Shock Working Group Registry
Condition:   Cardiogenic Shock Interventions:   Drug: Vasopressor;   Drug: Inotrope;   Device: Acute Mechanical Circulatory Support Devices Sponsors:   Tufts Medical Center;   Abbott;   Boston Scientific Corporation;   Abiomed Inc.;   Getinge Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 23, 2020 Category: Research Source Type: clinical trials